Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumours, has collaborated with United States-based Merck (known as MSD outside the US and Canada), through a subsidiary.
It was reported yesterday that the contract has been signed to assess Tessa Therapeutics' armoured human papillomavirus-specific T cell (HPVST) therapy, or TT12, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.
According to the contract, Tessa Therapeutics will conduct a multi-centre Phase 1b/2 trial to assess the safety and efficacy of the combination. The trial is planned for commencement in the United States, Singapore and South Korea. The company's product is an autologous cell therapy product composed of HPVSTs that have been trained to target HPV 16/18 antigens and genetically modified with a decoy TGF-beta receptor to overcome the suppressive tumour microenvironment.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
RyboDyn joins Lilly Gateway Labs' innovation hub
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study